News

Arrowhead Pharmaceuticals: A Reluctant Sell Rating Explained (Rating Downgrade)
Arrowhead Pharmaceuticals, Inc.'s deal with Sarepta expands its pipeline, but limited plozasiran market and competition ...
Meet the New Group of Weight-Loss Drugs. The Industry Is Betting Big on Amylin.
After the slimming effect of Ozempic and Zepbound earned billions for Novo Nordisk and Eli Lilly, another class of ...
Investor's Business Daily on MSN14h
Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly
Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.
Verywell Health15h
Not an 'Easy Way Out': How GLP-1 Users Navigate the Stigma of Weight Loss Drugs
Despite her active and healthy lifestyle, Sasha Barden felt stuck in her weight loss journey. She decided to try GLP-1 medications to support her weight loss goal. After six months on Wegovy ...
Viking Therapeutics: Obesity Candidates Must Prove Their Edge As Market Matures (Upgrade)
Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...